EBOO and Ozone Autohemotherapy: What the Evidence Actually Supports

What EBOO Is, and What Isn't in Dispute

EBOO stands for extracorporeal blood oxygenation and ozonation. Blood is withdrawn, run through a continuous extracorporeal circuit, exposed to a controlled mixture of medical oxygen and ozone gas, filtered, and reinfused. It is a more intensive variant of "major ozone autohemotherapy," which withdraws and reinfuses a smaller fixed volume of ozonated blood without a continuous circuit. The circuit itself, drawing blood, treating it, and returning it, is a well understood category of medical technique used routinely in dialysis and apheresis. What is not established is that adding ozone gas to that circuit produces the clinical benefits it is marketed for.[2]

The proposed mechanism is what its developers call "controlled oxidative stress": a brief, deliberate rise in reactive oxygen species intended to trigger the body's own antioxidant enzyme response, along with effects on platelets and circulation. That is a real, testable pharmacological hypothesis, not something invented for marketing. But the scientists who developed EBOO have themselves written that clinical application and validation of the technique "have been so far largely insufficient," and that statement has not been overturned by newer trials.[2]

No form of ozone gas or ozone-based systemic therapy holds FDA approval for any medical indication. Federal regulation classifies ozone as a toxic gas with no known useful medical application. This is a regulatory position, not a clinical trial finding, but it is directly relevant context for anyone weighing a marketed claim that ozone therapy treats or prevents a specific condition.[10]

What the Evidence for Peripheral Artery Disease Actually Shows

The foundational trial for EBOO in peripheral artery disease enrolled 28 patients, randomized them to EBOO or intravenous prostacyclin, and delivered a total of 210 treatments with no reported adverse effects. The EBOO group showed significant improvement in skin lesions, pain, itching, and the sensation of "heavy legs" compared with the prostacyclin group. That is a genuine positive finding worth reporting honestly.[1]

But the same trial found no significant change in objective vascularization or perfusion measures in either group. Patients felt and reported improvement in symptoms without a matching improvement in the underlying vascular measurements the trial was also tracking. The trial was small, unblinded, run at a single center, and has not been independently replicated in the roughly twenty years since it was published. That is a thin evidentiary base for a therapy still marketed today for peripheral artery disease.[1]

What the Evidence Shows for the Other Conditions Ozone Therapy Is Marketed For

For diabetic foot ulcers, a Cochrane systematic review pooling three randomized trials and 212 participants found no significant difference in the number of ulcers healed with ozone therapy compared with antibiotics or usual care. The certainty of evidence was graded low to very low across every outcome measured, and the review authors concluded they could not draw firm conclusions given the high or unclear risk of bias, small sample sizes, and short follow-up in the available trials.[3]

For shingles-related nerve pain, a 2026 meta-analysis pooling 20 randomized trials and 1,519 patients found a significant reduction in pain scores and inflammatory markers with ozone autohemotherapy, with no significant difference in adverse events compared with standard care. This is the largest and most favorable body of evidence in this review. Even so, the authors graded certainty as very low to low for most outcomes and cautioned that results should be interpreted carefully given heterogeneity between the pooled trials.[6]

For fibromyalgia, the available data is a retrospective observational study reporting improvements in pain, function, quality of life, and sleep after major ozone autohemotherapy. There was no control group and no randomization, so it cannot rule out placebo response or the natural waxing and waning of fibromyalgia symptoms over time. This kind of study can generate a hypothesis; it cannot confirm one.[8]

For dry age-related macular degeneration, a randomized but unblinded trial of 140 eyes found that 25 percent of ozone-treated eyes gained at least one line of vision at 12 months versus 0 percent of controls, alongside favorable changes in oxidative stress markers. This trial used major autohemotherapy, not the EBOO device specifically, and the authors themselves noted the absence of corroborating imaging data to support the vision finding.[4]

A 2026 umbrella review pooling seven meta-analyses across dental, wound, and infectious disease indications found partial benefit in dental indications and a surrogate, clinically unimportant effect in COVID-19, but no benefit at all for diabetic foot ulcer healing, the only wound indication it studied. Certainty of evidence was low or very low throughout, and the review authors concluded that routine clinical use is not justified. This review did not evaluate EBOO specifically, and it did not evaluate any of the detox, immune-boosting, or anti-aging claims that are commonly attached to ozone therapy marketing. No source in this review supports those specific claims.[5]

The Trap: A Marker Moving Is Not the Same as a Patient Getting Better

Ozone therapy research leans heavily on biomarkers: reactive oxygen metabolite levels going down, antioxidant capacity going up, inflammatory markers shifting favorably. Those changes are real and measurable, but they are not the same thing as a patient walking farther without leg pain, an ulcer closing, or a stroke being prevented. The peripheral artery disease trial illustrates the gap directly: patients reported meaningfully less pain and fewer skin lesions, but the objective vascular perfusion measures in the same patients did not improve. When a symptom score moves and the underlying physiology does not, that is worth naming rather than quietly folding into a single "it worked" narrative, especially in an unblinded trial where a demanding infusion comparator can itself inflate reported symptom relief.

What Remains Uncertain, and a Signal Toward Harm

A 2025 randomized pilot trial of ozonated blood in 60 patients with severe COVID-19 found a non-significantly higher mortality rate in the ozone group and a significantly higher rate of ICU transfer, 42.3 percent versus 10.3 percent in controls. The trial was small, unblinded, and underpowered to detect a mortality difference with confidence. But the direction of the finding, toward harm rather than benefit, matters and should not be omitted just because the sample was small. It is the only randomized trial in this evidence set testing ozone therapy in a critically ill population, and it did not show benefit.[7]

A 2024 case report described a 58-year-old woman who developed acute stroke symptoms from cerebral gas embolism during an intradiscal oxygen-ozone injection for spinal pain; she recovered fully by one year. This was an intradiscal injection procedure, not the EBOO extracorporeal circuit, so it does not transfer directly to EBOO's risk profile. But it documents that gas embolism is a real, reported complication in the broader class of medical ozone procedures, and it is the kind of low-frequency, high-severity risk that a short course of treatment can obscure.[9]

None of the sources in this review provide controlled clinical trial evidence for detox, general immune support, or anti-aging, the claims most commonly used to market ozone therapy and EBOO directly to healthy or worried-well patients. Those claims rest on the oxidative stress mechanism hypothesis, not on outcome data in humans. A plausible mechanism is not evidence of benefit until it is tested against a comparator and a real endpoint.[2][5]

What this means for you

Given this evidence, AION does not offer EBOO or ozone autohemotherapy as a first-line or standalone treatment for peripheral artery disease, diabetic foot ulcers, chronic pain, or post-viral fatigue, and does not market it for detox, immune support, or anti-aging. If it comes up in your care, it is discussed as an experimental adjunct, not a substitute for guideline-based vascular, wound-care, or pain management, and only after diagnostics establish what is actually driving your symptoms.

There is no fixed protocol to state as settled fact, because none exists in the controlled literature. Your physician decides case by case whether an experimental therapy with this evidence profile is appropriate for you, weighing the negative COVID-19 signal, the reported gas embolism risk, and the absence of FDA approval. Informed consent for this therapy means telling you plainly what is in this review: promising in narrow, small trials for a couple of specific uses, unproven or negative for others, and not something the evidence currently supports as routine care.